Does Ceftriaxone (Rocephin) followed by a 10-day course of Amoxicillin-Clavulanate (Augmentin) increase the risk of Clostridioides difficile (C diff) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk of C. difficile Infection with Ceftriaxone Followed by Amoxicillin-Clavulanate

Yes, this antibiotic regimen places the patient at increased risk for C. difficile infection, with the risk elevated up to sixfold during therapy and for one month afterward. 1

Understanding the Specific Risk Profile

Both antibiotics in this sequential regimen are independently associated with CDI risk:

  • Ceftriaxone (third-generation cephalosporin) has traditionally been considered to pose significant CDI risk, with cephalosporins showing a weighted pooled resistance rate of 47% and an odds ratio of 4.47 for community-associated CDI 2, 3

  • Amoxicillin-clavulanate (penicillin combination) is among the antibiotics traditionally associated with increased CDI risk, with penicillins showing an odds ratio of 3.25 for community-associated CDI 1, 3

  • The 10-day duration of the Augmentin course further amplifies risk, as longer antibiotic duration is directly associated with increased CDI incidence—a 10-day course incurs 12% more risk compared to a 7-day course 4

Key Risk Factors to Assess

The patient's individual risk factors substantially modify CDI likelihood 1:

  • Age >65 years 1
  • Recent hospitalization or healthcare facility exposure 1
  • Proton pump inhibitor (PPI) use, which increases CDI risk (OR 1.26-1.39) and should be avoided if possible during and after this antibiotic course 1, 5
  • Previous CDI episode, which dramatically increases recurrence risk 1
  • Immunocompromised status or immunosuppressive therapy 1
  • Severe underlying disease or advanced comorbidities 1

Clinical Management Recommendations

Discontinue the inciting antibiotic as soon as clinically appropriate to reduce recurrence risk 6

Avoid unnecessary PPI use during and after this antibiotic course, as PPIs independently increase CDI risk 1

There is insufficient evidence to recommend prophylactic anti-C. difficile agents (like vancomycin) for patients receiving this regimen unless they have multiple prior CDI episodes 1, 5

Important Caveats

  • A single dose of ceftriaxone carries substantially less risk than prolonged courses, so the initial Rocephin administration contributes less to overall risk than the subsequent 10-day Augmentin course 1

  • The cumulative antibiotic exposure (sequential use of two different agents) compounds the risk beyond what either agent would pose individually 1

  • Even limited antibiotic exposure increases patients' risk for both C. difficile colonization and infection 1

  • The risk remains elevated for one month after completing antibiotics, so vigilance for CDI symptoms should extend beyond the treatment period 1

References

Guideline

Risk of C. difficile Infection with Antibiotic Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Clostridioides difficile Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.